transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(+), CD3 (+) and Mac-1 (+) cells in lymphoid organs and peritoneal cavity.

Författare och institution:
Mikael Brisslert (Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning); Sylvie Amu (Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning); Rille Pullerits (Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning)
Publicerad i:
Cell and Tissue Research, 351 ( 1 ) s. 139-48
Artikel, refereegranskad vetenskaplig
Fulltextlänk (lokalt arkiv):
Sammanfattning (abstract):
Receptor for advanced glycation end products (RAGE) is a pattern recognition receptor that binds a variety of pro-inflammatory ligands. Its soluble form, sRAGE, can compete for ligand binding and thereby have an anti-inflammatory effect. We have recently reported that sRAGE also exerts pro-inflammatory and chemotactic properties suggesting a dual role for sRAGE in immune modulation. Our present aim was to analyse the immunomodulatory properties of sRAGE in vivo with respect to acquired immunity. Naive mice were treated intra-peritoneally with sRAGE and cells from peritoneal lavage, spleens and bone marrow were examined. Mice treated with sRAGE displayed an increased leucocyte count in the peritoneal cavity, enlarged spleens and increased cellularity compared with vehicle-treated animals. Furthermore, sRAGE-treated mice had a significantly increased frequency and number of CD19(+) B cells in spleen and a reduced frequency of CD19(+) B cells in bone marrow compared with controls. Functionally, splenocytes from sRAGE-treated mice showed elevated IgG production and up to a four-fold increased IgM secretion compared with control animals and produced significantly higher levels of interleukin-10, interferon-γ and interleukin-6 in response to lipopolysaccharide stimulation. Our results suggest that sRAGE has immunomodulatory properties, since intra-peritoneal administration of sRAGE into healthy mice leads to rearrangements in cellular composition in the bone marrow and spleen. Moreover, the administration of sRAGE directs B cells into the spleen and towards differentiation. Our novel findings indicate that sRAGE exerts an effect on the cells of adaptive immunity.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper ->
Immunologi inom det medicinska området ->
soluble RAGE, B cell, CD19, CD3, Mac-1, immunomodulation, antibodies
Postens nummer:
Posten skapad:
2012-12-18 13:19
Posten ändrad:
2013-03-14 08:19

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007